**Important Patient Notice**

**Mounjaro (Tirzepatide) Prescribing**

From June 23, 2025, NHS England has approved a new medication called Mounjaro (tirzepatide) for weight management and type 2 diabetes in patients who meet specific criteria.

We understand that some patients may be eager to access this treatment, particularly following recent media coverage. However, we want to be open with you about the current situation.

At present, our local NHS Integrated Care Board (ICB) has not commissioned a service and are unable to provide any additional support or funding for GP practices to safely deliver this treatment. Prescribing Mounjaro involves careful eligibility assessments, ongoing monitoring, and structured follow-up, all of which require time, training, and resources that general practices are not currently funded for.

**As such, we are currently unable to offer Mounjaro prescriptions or assessments through our GP surgery.**

We understand this may be frustrating, and we hope that our ICB will work with practices to develop a safe and sustainable service in the near future. In the meantime, patients who believe they may benefit from Mounjaro should speak with their hospital specialist if they are under the care of one or wait for further updates when more clarity is available.

Please note that we are unable to answer any complaints that result from any unhappiness at our inability to prescribe Mounjaro. These comments or complaints are best addressed to the ICB patient experience team by contacting them:

Lancashire and South Cumbria ICB

email: lscicb-fw.patientexperience@nhs.net or call 0300 373 3550.

North East and North Cumbria ICB

email: nencicb.complaints@nhs.net or call 0191 374 4218

Thank you for your understanding and continued support.

(Practice Name)